Prevention of TB in areas of low incidence

European Respiratory Monograph

Volumn 58, Issue , 2012, Pages 72-83

  Diel, Roland ^a   Nienhaus, Albert ^b,c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Institution for Statutory Accident Insurance and Prevention in the Health and Welfare Services   (Germany)

Author keywords

Bacille calmette gu rin vaccination; Immigrant screening; Latent tuberculosis; Multidrug resistant tuberculosis; Targeted testing

Indexed keywords

EID: 84870795535     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10022811     Document Type: Article

References (76)

1. Diel R, Schneider S, Meywald-Walter K, et al. Epidemiology of tuberculosis in Hamburg, Germany: long-term population-based analysis applying classical and molecular epidemiological techniques. J Clin Microbiol 2002; 40: 532-539.
2. Mor Z, Migliori GB, Althomsons SP, et al. Comparison of tuberculosis surveillance systems in low-incidence industrialised countries. Eur Respir J 2008; 32: 1616-1624.
3. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161: S221-S247.
4. Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet 2003; 3: 624-632.
5. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-2067.
6. Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 2011; 24: 351-376.
7. Horsburgh CR Jr, O'Donnell M, Chamblee S, et al. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med 2010; 182: 420-425.
8. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 1999; 2: CD001363.
9. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin - a meta-analysis. Chest 1991; 99: 465-471.
10. Garibaldi RA, Drusin RE, Ferebee SH, et al. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972; 106: 357-365.
11. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: A US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001.
12. Thompson NJ. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
13. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018.
14. Jasmer RM, Snyder DC, Chin DP, et al. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 162: 1648-1652.
15. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137: 640-647.
16. McNeill L, Allen M, Estrada C, et al. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis. Chest 2003; 123: 102-106.
17. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: 443-447.
18. Leung CC, Law WS, Chang KC, et al. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest 2003; 124: 2112-2118.
19. Menzies D, Dion MJ, Rabinovitch B, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-449.
20. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128: 116-123.
21. Tortajada C, Martinez-Lacasa J, Sanchez F, et al. Tuberculosis Prevention Working Group. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis 2005; 9: 276-281.
22. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007; 45: 715-722.
23. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149: 689-697.
24. Hawken MP, Meme HK, Elliott LC, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11: 875-882.
25. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337: 801-808.
26. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000; 283: 1445-1450.
27. Sterling TR, Villarino ME, Borisov AS, et al. Three months of once-weekly rifapentine and isoniazid for M. tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
28. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365: 11-20.
29. Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60: 1650-1653.
30. Holland DP, Sanders GD, Hamilton CD, et al. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009; 179: 1055-1060.
31. Linas BP, Wong AY, Freedberg KA, et al. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011; 184: 590-601.
32. Denkinger CM, Dheda K, Pai M. Guidelines on interferon-c release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect 2011; 17: 806-814.
33. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-c release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45-55.
34. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-c release assays and tuberculin skin testing for predicting progression from latent TB infection to disease state: a meta-analysis. Chest 2012; 142: 63-75.
35. LoBue PA, Enarson DA, Thoen TC. Tuberculosis in humans and its epidemiology, diagnosis and treatment in the United States. Int J Tuberc Lung Dis 2010; 14: 1226-1232.
36. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
37. Moore-Gillon J, Davies PD, Ormerod LP. Rethinking TB screening: politics, practicalities and the press. Thorax 2010; 65: 663-665.
38. Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK, 2010. London, Health Protection Agency Centre for Infections, 2010.
39. Laifer G, Widmer AF, Simcock M, et al. TB in a low-incidence country: differences between new immigrants, foreign-born residents and native residents. Am J Med 2007; 120: 350-356.
40. Thorpe LE, Laserson K, Cookson S, et al. Infectious tuberculosis among newly arrived refugees in the United States. N Engl J Med 2004; 350: 2105-2106.
41. Maloney SA, Fielding KL, Laserson KF, et al. Assessing the performance of overseas tuberculosis screening programs. Arch Intern Med 2006; 166: 234-240.
42. Klinkenberg E, Manissero D, Semenza JC, et al. Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. Eur Respir J 2009; 34: 1180-1189.
43. Diel R. Pravention und Kontrolle der Tuberkulose. [Prevention and control of tuberculosis.] Pneumologe 2007; 4: 187-193.
44. Cain KP, Haley CA, Armstrong LR, et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med 2007; 175: 75-79.
45. National Institute for Health and Clinical Excellence. Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, NICE, 2006.
46. National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at the National Institute for Health and Clinical Excellence. Tuberculosis (CG117). Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, Royal College of Physicians, 2011.
47. Pareek M, Watson JP, Ormerod LP, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011; 11: 435-444.
48. Hardy AB, Varma R, Collyns T, et al. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 2010; 65: 178-180.
49. Zwerling A, Behr MA, Verma A, et al. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 2011; 8: e1001012.
50. Fine PE. Bacille Calmette-Guérin vaccines: a rough guide. Clin Infect Dis 1995; 20: 11-14.
51. Fine PEM, Carneiro IA, Milstien J, et al. Issues relating to the use of BCG in immunization programmes: a discussion document. Geneva, World Health Organization, 1999.
52. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998; 2: 200-207.
53. Robert Koch Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2010. [Report on the epidemiology of Tuberculosis in Germany, 2010.] Berlin Robert Koch, Institute, 2012.
54. Manissero D, Lopalco PL, Levy-Bruhl D, et al. Assessing the impact of different BCG vaccination strategies on severe childhood TB in low-intermediate prevalence settings. Vaccine 2008; 26: 2253-2259.
55. Altes HK, Dijkstra F, Lugnèr A, et al. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment. Epidemiology 2009; 20: 562-568.
56. Rossignol L, Guthmann JP, Kernéis S, et al. Barriers to implementation of the new targeted BCG vaccination in France: a cross sectional study. Vaccine 2011; 29: 5232-5237.
57. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011; 11: 633-640.
58. Parliamentary questions 4 January 2011. Answer given by Ms Geoghegan-Quinn on behalf of the Commission E9505/2010. OJ C 265 E, 09/09/2011.
59. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; 1: CD000171.
60. Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-272.
61. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1-207.
62. Schaberg T, Bauer T, Castell S, et al. Empfehlungen zur Therapie, Chemopravention und Chemoprophylaxe der Tuberkulose im Erwachsenen- und Kindesalter. Deutsches Zentralkomitee zur Bekampfung der Tuberkulose (DZK), Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin (DGP). [Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP).] Pneumologie 2012; 66: 133-171.
63. Migliori GB, Sotgiu G, D'Ambrosio L, et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012; 39: 619-625.
64. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-1299.
65. Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010; 181: 743-751.
66. Bishai JD, Bishai WR, Bishai DM. Heightened vulnerability to MDR-TB epidemics after controlling drugsusceptible TB. PLoS ONE 2010; 5: e12843.
67. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. Stockholm, European Centre for Disease Prevention and Control, 2012.
68. CDC. Reported Tuberculosis in the United States, 2010. Atlanta, US Department of Health and Human Services, CDC, 2011.
69. Burman WJ, Reves RR. How much directly observed therapy is enough? Am J Respir Crit Care Med 2004; 170: 474-475.
70. Oren E, Winston CA, Pratt R, et al. Epidemiology of urban tuberculosis in the United States, 2000-2007. Am J Public Health 2011; 101: 1256-1263.
71. European Centre for Disease Prevention and Control. Management of contacts of MDR TB and XDR TB patients. Stockholm, ECDC, 2012.
72. Fraser A, Paul M, Attamna A, et al. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2006; 2: CD005435.
73. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265.
74. Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 995-1003.
75. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772.
76. Rossi C, Zwerling A, Thibert L, et al. Mycobacterium tuberculosis transmission over an 11-year period in a lowincidence, urban setting. Int J Tuberc Lung Dis 2012; 16: 312-318.